Audit: QRS - Cranberry for Health & Longevity

Audit conducted on 23/09/2026 05:39 using AI4L / Opus 5.5

Iterations

Summary

Items	Count
Total	94
Passed	86
Failed	0
N/A	8
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	At-a-glance, protocol, time-to-effect, gates, tiers, monitoring and qualitative items all trace to ER passages (e.g., Conclusion L426-430, Protocol L333-340, Practical Considerations L368, Monitoring L385-409).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Cautious phrasing kept: “has not been shown to treat” (ER L430), “theoretical additive bleeding” (ER L303), “possible raised INR” (ER L302).
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	No claim strengthened or softened; contraindication qualifiers (“unless INR is closely monitored”) kept verbatim.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Items stay in their ER categories; contraindications from the ER avoid-list, interactions from the ER interaction bullets, tiers from Expected Benefits / Potential Risks.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, study citations, expert names, NCT IDs or brand names appear in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	No attributions introduced.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Measured, evidence-weighted tone mirrors the ER (“best-supported”, “thinner”, “unsettled”).
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Content framed as findings and ER-derived gates, not clinical instructions.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person address.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms are glossed (PACs, BL-DMAC, anti-adhesion, INR, HbA1c, visual episodic memory).
2.8	Information is presented in a concise and very compact manner	🟢
2.9	It DOES NOT address the reader directly	🟢
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	Lede highlights susceptible groups and the non-treatment limit, relevant to proactive users.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	No “anti-aging” framing.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	No colloquial route or adverse-event wording (no “pill”, “by mouth”, “shot”, “bad reaction”).

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed headings, gate headings, tier labels and table headers match the template (QRS L440, L477, L519, L539, L551, L572, L592, L596-598, L733).
3.2	All “<span data-qrs-var="NAME">...</span>” from the [qrs_template] are present in the the QRS.	🟢	All template spans present, incl. page_title, header_, at_a_glance, action_1-3_, time_1-3*, benefits, stop_items, caution_items, risks_, marker_1-11_*, monitoring_cadence, qualitative_item_1-5.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	Head/CSS identical to template apart from the page_title value; footer and static text unchanged.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	🟢	The empty ER High risk tier is handled per 13.5 (hidden span) with an HTML comment quoting the ER’s “No risk reaches High” (QRS L575).
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels (“PAC-standardized extract”, “Juice”, “Time of day”) and interaction labels use the ER bold labels verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji in the QRS.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Sections condensed (interaction mitigations stripped, tier items reduced to headings); length is driven by the complete lists required by 9.5 and 14.2.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Metadata comment at QRS L2, directly after <!doctype html>.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	YAML delimited by — at L3 and L13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Values trimmed; only duration “00:02” quoted, which contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: cranberry_2026-0923-0221_Opus_ER.md
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.9.22 matches QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0923-0523
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5.5
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: cranberry_2026-0923-0221_Opus_QRS.html
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“Cranberry for Health & Longevity - Quick Reference Sheet” (L22).
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	L417.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	09/23/2026 from 2026-0923-0523 (L421).
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Opus 5.5 (L425).
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence	🟢	Opens with “Cranberry, a tart berry taken as juice, dried fruit or extract, is used to help prevent bladder infections”.
7.2	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Condenses Conclusion paragraphs 1-3 (ER L426-430).
7.3	[at_a_glance] is no longer than 70 words	🟢	70 words.
7.4	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢
7.5	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; warfarin glossed as “the blood thinner”.
7.6	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢
7.7	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
8.2	[stop_items] represent the Contraindications from the ER	🟢	All five items from ER “Populations who should avoid Cranberry” (ER L314-318).
8.3	Individual [stop_items] are formatted as <li></li>	🟢
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Thresholds (40 mg/day, below 60%, above 7%, above 38 °C) preserved.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	No ranking notation in the ER.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	Section populated; ER names populations to avoid.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!-- empty: ER names no population that should avoid the intervention -->	N/A	Section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All nine ER interaction bullets (ER L302-310); none duplicates a contraindication.
9.3	Individual [caution_items] are formatted as <li></li>	🟢
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Mitigation and mechanism clauses stripped.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Example drug lists and thresholds (above 1 g daily) preserved.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	No ranking notation in the ER.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	Section populated; ER names interactions.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!-- empty: ER names no interaction that changes how the intervention is used -->	N/A	Section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	From ER Therapeutic Protocol (L333-340).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Extract dose, juice dose and time of day.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three actionable aspects exist in the ER.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Fewer UTIs (with anti-adhesion onset), vascular effects, memory changes (ER L368).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	High-tier UTI benefit first, then Low-tier vascular and memory.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three time-to-effect aspects exist in the ER.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	ER provides time-to-effect information.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Items reduced to ER benefit headings; “Conflicted” markers dropped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers have items.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	risks_high span set to display: none (L574); not filled with empty-state text.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All 11 ER biomarkers listed (ER L391-401).
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Cadence matches ER L387.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All 5 ER qualitative markers listed (ER L405-409).

Issues 23/09/2026 05:39

Pass rate 100.00%. No issues found.

Issues 23/09/2026 05:35

1. 2.7 — Unnecessary jargon on sheet: “cardiometabolic markers” (action_2_sub, line 461) and “Detects bleeding-risk potentiation” (marker_3_why, line 632) use specialist wording, and “antiplatelet drugs” (line 555) is left without the ER’s plain-language gloss.
2. 4.2 / 4.3 — Interaction labels abbreviated: The bold labels of four Key Interactions items (lines 554-556, 560) are shortened versions of the ER bold labels, e.g. “(blood thinners that block vitamin K recycling: …)” became “(blood thinners: …)” and “(which stop platelets clumping)”, “non-steroidal anti-inflammatory drugs,” and “which lower cholesterol” were dropped.

Fixes 23/09/2026 05:35

1. 2.7 — Unnecessary jargon replaced: Changed action_2_sub “for cardiometabolic markers” to “for heart and metabolic markers” and marker_3_why “Detects bleeding-risk potentiation” to “Detects a strengthened warfarin effect” (ER Risk Mitigation wording).
2. 4.2 / 4.3 / 2.7 — Interaction labels restored verbatim: Restored the full ER bold labels for the vitamin K antagonist, direct oral anticoagulant/antiplatelet, salicylate/NSAID and CYP-cleared drug items, including the glosses “that block vitamin K recycling”, “(which stop platelets clumping)”, “non-steroidal anti-inflammatory drugs,” and “which lower cholesterol”.

Issues 23/09/2026 05:32

1. 1.3 — Dropped “usually” hedge: action_1_sub (line 450) states “higher doses split into morning and evening”, while the ER Therapeutic Protocol (line 340) says higher doses are “usually” split, turning typical practice into a fixed rule.
2. 2.7 — Unexplained “anti-adhesion” jargon: “anti-adhesion” appears in action_3_sub (line 472) and time_1_sub (line 489) without any plain-language explanation of blocking bacteria from sticking to the bladder lining.
3. 4.2 / 4.3 — CYP interaction label altered: The Key Interactions bold label (line 560) reads “Drugs cleared by CYP2C9, CYP1A2 or CYP3A4 liver enzymes”, adding “liver enzymes” to the ER bold label “Drugs cleared by CYP2C9, CYP1A2 or CYP3A4” (ER line 304).

Fixes 23/09/2026 05:32

1. 1.3 — Restored “usually” hedge: Changed action_1_sub from “higher doses split into morning and evening” to “higher doses usually split into morning and evening”, matching the ER Therapeutic Protocol.
2. 2.7 — Explained “anti-adhesion” jargon: At its first use in action_3_sub, “anti-adhesion” became “urinary anti-adhesion (blocking bacteria from sticking to the bladder lining)”, taken from the ER Mechanism of Action.
3. 4.2 / 4.3 — Restored verbatim CYP label: Removed the inserted “liver enzymes” so the bold label now reads “Drugs cleared by CYP2C9, CYP1A2 or CYP3A4 (tizanidine, midazolam, statins such as atorvastatin)”, as in the ER.

Issues 23/09/2026 05:30

1. 2.7 — Unexplained specialist terms: “PACs” (line 447), “HbA1c” (line 545, ER gloss “3-month average blood sugar” dropped), “INR” (lines 543, 554), “Vitamin K antagonist anticoagulants”, “Direct oral anticoagulants”, “NSAIDs” and “CYP2C9, CYP1A2 or CYP3A4” (lines 554–560), “UTIs” (line 483) and “Visual episodic memory” (line 511) appear without the plain-language glosses the ER supplies.

Fixes 23/09/2026 05:30

1. 2.7 — Added plain-language glosses: Added the ER’s own glosses for “PACs” (tannin-like plant compounds), “HbA1c” (3-month average blood sugar), “INR” (a clotting test), vitamin K antagonist and direct oral anticoagulants (blood thinners), “NSAIDs” (common pain relievers), CYP enzymes (liver enzymes) and visual episodic memory (recall of seen events), and expanded time_1_label to “Fewer urinary tract infections (UTIs)”.

Issues 23/09/2026 05:26

1. 2.7 — Unexplained technical jargon: time_2_sub (line 500) adds the acronym “(FMD)” and action_1_sub (line 450) names the “BL-DMAC method” without the ER’s plain explanation “(a standardized dye assay)”.
2. 9.4 — Mechanistic rationale retained: The Direct oral anticoagulants and antiplatelet drugs interaction (line 555) keeps the rationale “from salicylate content” instead of just the key fact.

Fixes 23/09/2026 05:26

1. 2.7 — Unexplained technical jargon: Removed “(FMD)” from time_2_sub (“Blood vessel function”) and added the ER’s explanation to action_1_sub (“BL-DMAC method (a standardized dye assay)”).
2. 9.4 — Mechanistic rationale retained: Dropped “from salicylate content” from the Direct oral anticoagulants and antiplatelet drugs item, leaving “Monitor; no documented interaction, but theoretical additive bleeding”.